TKNO Stock Overview
Produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Alpha Teknova, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.75 |
52 Week High | US$4.27 |
52 Week Low | US$1.66 |
Beta | 0.39 |
1 Month Change | -8.38% |
3 Month Change | -38.81% |
1 Year Change | -55.47% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -93.00% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Shareholder Returns
TKNO | US Life Sciences | US Market | |
---|---|---|---|
7D | -4.4% | -3.9% | -1.0% |
1Y | -55.5% | 6.5% | 25.2% |
Return vs Industry: TKNO underperformed the US Life Sciences industry which returned 6.5% over the past year.
Return vs Market: TKNO underperformed the US Market which returned 25.2% over the past year.
Price Volatility
TKNO volatility | |
---|---|
TKNO Average Weekly Movement | 11.2% |
Life Sciences Industry Average Movement | 6.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TKNO's share price has been volatile over the past 3 months.
Volatility Over Time: TKNO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 211 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
TKNO fundamental statistics | |
---|---|
Market cap | US$73.48m |
Earnings (TTM) | -US$36.06m |
Revenue (TTM) | US$36.85m |
1.9x
P/S Ratio-2.0x
P/E RatioIs TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TKNO income statement (TTM) | |
---|---|
Revenue | US$36.85m |
Cost of Revenue | US$26.77m |
Gross Profit | US$10.08m |
Other Expenses | US$46.14m |
Earnings | -US$36.06m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.88 |
Gross Margin | 27.36% |
Net Profit Margin | -97.85% |
Debt/Equity Ratio | 15.8% |
How did TKNO perform over the long term?
See historical performance and comparison